7 October 2025 in NAR Genomics and Bioinformatics
Sugar beet (Beta vulgaris ssp. vulgaris) is an important crop plant serving as a major source of sugar, particularly in Europe. Sugar beet research using the genotype KWS2320 has a long-standing history, and many datasets and studies exist that use this genotype as a reference. Here, we present a high-quality genome sequence of sugar beet genotype KWS2320 based on long-read sequencing data as well as an evidence-based gene set employing billions of mRNA (messenger RNA)-seq reads as transcript evidence. The assembly, referred to as RefBeet-3.0, was built using Pacific Biosciences data and was integrated with Bionano optical maps, Oxford Nanopore data, and various additional genomic resources. RefBeet-3.0 comprises 648 Mb in nine pseudochromosomes and further sequences with a total N50 size of 61.5 Mb. The gene set BeetSet-3 consists of 28 271 genes of which 25 824 could be functionally annotated based on sequence homology to orthologous groups. The assembly is highly complete and has a high sequence accuracy in absolute terms and in comparison to existing sugar beet assemblies. RefBeet-3.0 and BeetSet-3 will serve as comprehensive resources for future studies on sugar beet and other plants, as well as for breeding activities.
7 August 2023 in Proceedings of the National Academy of Sciences
Current knowledge of cancer genomics remains biased against noncoding mutations. To systematically search for regulatory noncoding mutations, we assessed mutations in conserved positions in the genome under the assumption that these are more likely to be functional than mutations in positions with low conservation. To this end, we use whole-genome sequencing data from the International Cancer Genome Consortium and combined it with evolutionary constraint inferred from 240 mammals, to identify genes enriched in noncoding constraint mutations (NCCMs), mutations likely to be regulatory in nature. We compare medulloblastoma (MB), which is malignant, to pilocytic astrocytoma (PA), a primarily benign tumor, and find highly different NCCM frequencies between the two, in agreement with the fact that malignant cancers tend to have more mutations. In PA, a high NCCM frequency only affects the BRAF locus, which is the most commonly mutated gene in PA. In contrast, in MB, >500 genes have high levels of NCCMs. Intriguingly, several loci with NCCMs in MB are associated with different ages of onset, such as the HOXB cluster in young MB patients. In adult patients, NCCMs occurred in, e.g., the WASF-2/AHDC1/FGR locus. One of these NCCMs led to increased expression of the SRC kinase FGR and augmented responsiveness of MB cells to dasatinib, a SRC kinase inhibitor. Our analysis thus points to different molecular pathways in different patient groups. These newly identified putative candidate driver mutations may aid in patient stratification in MB and could be valuable for future selection of personalized treatment options.
12 January 2026 in Neuro-Oncology Advances
Gliomas are the most common malignant primary tumor of the central nervous system and show a high mortality, particularly at higher grades. Cancer predisposition syndromes and common low-penetrance single nucleotide polymorphisms have been shown to contribute to glioma risk, but the contribution of rare germline variants remains incompletely understood. Here, we investigated rare germline variants in glioma patients. We performed whole-genome sequencing on 113 glioma patients from Northern Sweden, analyzing rare germline variants across 651 genes. Variants were compared to population controls (ACpop, gnomAD) and validated in TCGA glioma data, a UK Biobank glioma nested case–control study, and a separate cohort of 105 Swedish glioblastomas. 17.6% of glioma cases carried a Pathogenic or Likely Pathogenic (P/LP) variant within 1 of the 651 genes, and the number of alleles carrying a P/LP was significantly more than in the reference data (P = ). Many of the observed candidate genes also harbored P/LP variants in our Swedish validation cohort. Overall, gene-based comparison of rare coding variants indicated an enrichment in several genes, including TP53, CREBBP, and DNMT3A. Rare P/LP germline variants were more frequent among glioma patients than in the reference population within our predefined gene set. These results suggest a contribution of rare germline variants to glioma risk, particularly in genes involved in DNA repair. While several genes are indicated as enriched with rare variants, only TP53 validates across all 3 patient sets.